Alerity Therapeutics Announces Presentation Of New Data Analyses From The Phase 2 Trial Of ATH434, Demonstrating Clinical Efficacy In Patients With Multiple System Atrophy At The American Academy of Neurology Annual Meeting

Alterity Therapeutics Ltd. Sponsored ADR

ATHE

0.00

- ATH434 reduced functional decline vs placebo at Week 52 on MuSyCA, a newly described MSA composite scale -

- Effects seen on both daily function and neurological examination, consistent with previously reported activity on modified UMSARS Part I -

- Presentation reinforces ATH434's clinical profile ahead of Phase 3 engagement with regulators -

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.